Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 30Docetaxel 10Cetuximab 10Trastuzumab 9Paclitaxel 7Nivolumab 6Magnetic Resonance Spectroscopy 6palbociclib 5cemiplimab 5Gemcitabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5Biopsy 5durvalumab 4atezolizumab 4Surveys and Questionnaires 4Radiotherapy 4Fulvestrant 4Fluorodeoxyglucose F18 4Drug Therapy 4Cisplatin 4selpercatinib 3poly ICLC 3pazopanib 3fludarabine 3avelumab 3Taxes 3Sunitinib 3Specimen Handling 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Canagliflozin × Head & Neck × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡